7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one | 100667-52-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one
• 英文别名: (E)-7-(4-hydroxyphenyl)-1-phenylhept-4-en-3-one
• CAS: 100667-52-5
• 化学式: C₁₉H₂₀O₂
• 分子量: 280.4
• InChiKey: VPCHZECKYCDVSA-WEVVVXLNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Methods and compositions for enhancing neuron growth and survival
  申请人：Crabtree R. Gerald

  公开号：US20050014680A1

  公开（公告）日：2005-01-20

  Pharmaceutical compositions of NF-AT agonists may be used to promote nerve regeneration or to reduce or inhibit secondary nerve degeneration which may otherwise follow primary CNS or PNS injury, e.g., trauma (e.g., blunt trauma, penetrating trauma), compression [e.g., compression due to tendons and/or inflamed synovial membrane such as in carpal tunnel syndrome], bones [for instance sciatica], or growths [benign or cancerous, including growth of the nerves themselves or of surrounding tissue]) hemorrhagic stroke, ischemic stroke or damages caused by surgery such as tumor excision. In certain embodiments, NF-AT agonists may be used to treat spinal cord injuries and promote nerve grafts.

  NF-AT激动剂的药物组合物可用于促进神经再生或减少或抑制继发性神经变性，否则继发性神经变性可能是继原发性中枢神经系统或前枢神经系统损伤之后发生的，如创伤（如钝伤、穿透性创伤）、压迫[如肌腱和/或发炎的滑膜导致的压迫，如腕管综合征]、骨骼[如坐骨神经痛]或增生[良性或癌症，包括神经本身或神经增生]、出血性中风、缺血性中风或肿瘤切除等手术造成的损伤。在某些实施方案中，NF-AT 激动剂可用于治疗脊髓损伤和促进神经移植。
• Methods and agents for enhancing bone formation or preventing bone loss
  申请人：Crabtree R. Gerald

  公开号：US20050171015A1

  公开（公告）日：2005-08-04

  The present invention provides methods for (i) reducing loss of bone mass or bone density, (ii) increasing bone mass or bone density, (iii) maintaining bone mass or bone density, and/or (iv) reducing loss of calcium from bone, comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. The method could be used for treating, preventing or delaying a bone condition. The invention further provides a method for promoting healing of bone fractures or bone defects comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. Compositions comprising NFAT agonists can also be used for the in vitro or in vivo generation of bone tissue. The invention also provides screening methods for agents which promotes, maintains, or reduces the loss of, bone mass, and the use of such agents for therapeutic purposes.

  本发明提供了用于(i)减少骨量或骨密度损失，(ii)增加骨量或骨密度，(iii)维持骨量或骨密度，和/或(iv)减少骨钙损失的方法，包括：向受试者施用治疗有效量的NFAT激动剂。该方法可用于治疗、预防或延缓骨病。本发明进一步提供了一种促进骨折或骨缺损愈合的方法，包括：向受试者施用治疗有效量的 NFAT 激动剂。包含 NFAT 激动剂的组合物还可用于体外或体内生成骨组织。本发明还提供了促进、维持或减少骨量损失的制剂的筛选方法，以及将此类制剂用于治疗目的的方法。
• Diarylheptanoid compounds and uses thereof
  申请人：Rafi M. Mohamed

  公开号：US20050215635A1

  公开（公告）日：2005-09-29

  The present invention relates to diarylheptanoid compounds and compositions comprising a diarylheptanoid compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more diarylheptanoid compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more diarylheptanoid compounds. The present invention further relates to articles of manufacture comprising one or more diarylheptanoid compounds.

  本发明涉及二芳基庚烷类化合物和包含二芳基庚烷类化合物的组合物。本发明还涉及通过向有需要的受试者施用一种或多种二芳基庚烷类化合物来预防或治疗各种疾病和失调的方法。特别是，本发明涉及通过向有需要的受试者施用一种或多种二芳基庚烷类化合物来预防或治疗癌症或炎症性疾病的方法。本发明还涉及包含一种或多种二芳基庚烷类化合物的制造品。
• METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES
  申请人：University of Houston System

  公开号：EP3962559A1

  公开（公告）日：2022-03-09
• [EN] COMBINATION OF LYSOSOMOTROPIC OR AUTOPHAGY MODULATING AGENTS AND A GSK-3 INHIBITOR FOR TREATMENT OF CANCER<br/>[FR] COMBINAISON D'AGENTS LYSOSOMOTROPIQUES OU DE MODULATION DE L'AUTOPHAGIE ET D'UN INHIBITEUR DE GSK-3 POUR LE TRAITEMENT DU CANCER
  申请人：UNIV BASEL

  公开号：WO2013182519A1

  公开（公告）日：2013-12-12

  The invention relates to combinations oflysosomotropic agent or agents modulating autophagy, such as chloroquine, 3-methyladenine or bafilomycin A1, and a GSK-3 inhibitor, such as (2'Z,3'E)-6-bromoindirubin-3'-acetoxime, TDZD-8 or L803-mts. These compositions are useful in the treatment of cancer, proliferative inflammatory diseases, degenerative diseases and some infectious diseases, preferably cancer. The tumor cell survival is particularly dependent on proper endoplasmic reticulumf unction.